Adimab will license and transfer its proprietary antibody discovery platform to Biogen Idec and enable Biogen Idec researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies. Biogen Idec will receive a custom antibody library and will obtain a license to the Adimab Platform for use in its targeted therapeutic areas. Following GSK, Biogen Idec will be the second pharmaceutical company to internalize the Adimab platform. In addition, Biogen Idec has secured an option to receive continued improvements to the Adimab Platform, including access to new antibody libraries.
Over the past four years, Adimab has established collaborations with multiple pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK. Adimab's collaborations range from single-target funded discovery projects to larger, multi-target funded discovery collaborations, as well as full license, transfer and enablement of the Adimab Platform to pharma companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.